About TargetMol
Founded in 2015, TargetMol develops research tools and screening resources that support drug discovery, chemical biology and translational life science research. Headquartered in the Greater Boston area, the company focuses on small molecules, compound library design and biological screening technologies that enable researchers to investigate disease mechanisms, identify therapeutic targets and evaluate candidate compounds. Its expertise spans bioactive compounds, natural products, medicinal chemistry and computer-aided drug design (CADD), supporting applications across oncology, immunology, neuroscience, metabolism, cardiovascular research and other therapeutic areas.
TargetMol offers an extensive portfolio of more than 300 compound libraries, including bioactive, disease-focused, target-focused, natural product, fragment and drug-repurposing collections for high-throughput and high-content screening workflows. In addition, the company supplies small-molecule inhibitors, activators and agonists, recombinant proteins, peptides, antibodies and assay reagents used in target validation, pathway analysis, phenotypic screening and mechanism-of-action studies. Custom chemical synthesis and computational drug discovery services further support hit identification and lead optimisation programmes.
Europa Biosite subsidiaries distribute TargetMol products across Austria, Benelux, Canada, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland, United Kingdom and the United States of America.